ABC | Volume 111, Nº3, September 2018

Short Editorial Tanaka Secondary dyslipidemia in obese children Arq Bras Cardiol. 2018; 111(3):362-363 References This is an open-access article distributed under the terms of the Creative Commons Attribution License 1. ChandrasekharT,SuchitraMM,PallaviM,SrinivasaRaoPV,PallaviM,Sachan A. Risk factors for cardiovascular disease in obese children. Indian Pediatr. 2017;54(9):752-5. 2. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am. 2011,95(5):893-902. 3. Wang H, Peng DQ. New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis. 2011 Oct 12;10:176 4. Klop B, Cabezas MC. Chylomicrons: a key biomarker and risk fator for cardiovascular disease and for the understanding of obesity. Curr Cardiovasc Risk Rep. 2012.6(1):27-34. 5. Yin RX, Wu DF, Misao L, Aung LH, Cao XL, Yan TT, et al. Several genetic polymorphisms Interact with overweight/obesity to influence serum lipid levels. Cardiovasc Diabetol. 2012 Oct 8;11:123. 6. Sanchez-Moreno C, Ordovas JM, Smith CE, Craza JC, Lee YC, Garaulet M APOAS gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerids in a Mediterranean population. J Nutr.2012;141(5):380-5. 7. Ferguson MA, Alderson NL, Trost SG, Essig DA, Burke JR, et al. Effects of four diferente single exercice session on lipids, lipoproteins, and liporprotein lipase. J Appl Physiol. 1998;85(3):1169-74. 8. Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS,Gui J, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLos One. 2012;7(6):e39062. 9. Catapano AL, Reiner Z, Backer G, Graham I, Taskinen MR Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1):1-44 10. Berglun L, Brunzess JD, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-89. 11. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;97(5):350-5. 12. Watts GF, Karpe F. Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient? Expert Rev Cardiovasc Ther. 2011;9(8):987-97. 13. DujovneCA,WilliamsCA,WilliamsCD,ItoMK,Whatcombinationtherapywith astatin,efany,wouldyourecommend?CurrAtherosclerRep.2011;13(1):12-22. 14. RubenfireM, Brook RD, Rosenson RS. Treatingmixed hyerlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med. 2010;123(10:892-8. 15. Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-loweing drugs. Drugs. 2010;70(11):1363-79. 16. Radaelli G, Sausen G, Cesa CC, Portal VL, Pellanda LC. Dislipidemia secundáriaemcriançasobesas-Háevidênciasdetratamento farmacológico. Arq Bras Cardiol. 2018; 111(3):356-361. 363